Furthermore, to explore whether HR deficiency can indeed benefit TNBC patients’ response to ACT treatment, we determined the ACT chemotherapy failure-free interval (FFI) of patients based on the period from the end of treatment to tumour progression/recurrence or death (Fig. 3B). Here, HR is linked to neoplasm.